PRINT Teaming Profiles

Thank you for showing an interest in ARPA-H’s Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) program. This page is designed to help facilitate connections between prospective proposers. If either you or your organization are interested in teaming, please submit your information via the form below. Your details will then be added to the list below, which is publicly available.

PRINT anticipates that teaming will be necessary to achieve the goals of the program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal to the PRINT solicitation. For questions, please visit the PRINT portal.

PRINT Teaming Profile Form

Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.

Interested in learning more about the PRINT program?

Read the PRINT draft Innovative Solutions Opening.
Register to attend the virtual Proposers’ Day on May 7, 2024.
See the PRINT program overview page.

Teaming Profiles List

To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.

Organization name	Point of contact name	Point of contact email	Provide an additional point of contact for your organization's representative (email only)	Location	In 200 words or less, describe your organization's current research focus areas	In 200 words or less, tell us what your organization is looking for in potential teaming partners	Which technical areas within PRINT does your organization have the capacity to address?
Auxilium Biotechnologies	Isac Lazarovits	Isac@auxiliumbio.com	Info@auxiliumbio.com	San Diego, CA	Sophisticated 3D bioprinting capabilities for tissue engineering including high resolution, fast printing (minutes compared to days). We print clinical size scaffolds that retain cell viability. Our devices have been tested in-vivo in small and large animal models. Additionally, we have bioprinting capabilities on the International Space Station, where we leverage microgravity to print complicated features.	Looking to partner with those that can satisfy technical areas 1 and 2.	Technical area 3: organ biofabrication and testing;
Advanced Solutions Life Sciences	James Hoying	jhoying@advancedsolutions.com		Louisville, KY	Advanced Solutions Life Sciences (ASLS) is dedicated to the discovery, design, and development of integrated software, hardware, and bioware solutions for the life sciences, biotechnology, and biomedical fields. ASLS, a subsidiary of Advanced Solutions, Inc. with over 70 employees, is comprised of experienced engineering and science teams including systems engineers, software engineers, mechanical engineers, simulation engineers, electrical engineers, bioengineers, AI experts, tissue biologists, experimental scientists, and translational scientists. ASLS works with a wide breadth of customers, collaborators, and partners to advance innovative health care solutions. ASLS is a manufacturer of the BioAssemblyBot robotic biofabrication and biomanufacturing technology platform, with a focus on integrating 3D and 4D bioprinting approaches into fully automated, compliant biomanufacturing solutions. We work with a variety of partners in developing protocols and solutions for the manufacture of therapeutic vascularized tissues and tissue products.	We are interested in partnering with teams to develop and implement compliant tissue and organ manufacturing solutions at either centralized or point-of-care facilities.	Technical area 2: large scale manufacturing ;Technical area 3: organ biofabrication and testing;
Cytoink Solutions, Inc.	Martin Tomov	martin@cytoink.com	mihail@cytoink.com	Rockville, Maryland	Cytoink Solutions has over a decade of experience in tissue engineering, biomaterials, and cell-based organ models that we leverage to help develop tailored functional tissue platforms to a customer’s needs, such as drug discovery, disease modeling, and biomedical device development, with a specific focus on bioprinted, functional organ models. We are currently working with 10 defined biomaterial building blocks that can be freely combined and further modified with tissue-specific bioactive molecules to model a wide range of tunable organ targets (lings, kidney, liver, cardiovascular, etc.). Our biomaterials have been tested to maintain cytocompatibility and specific cell functions with different cell types, including immortalized (endothelial cells, hepatocytes, smooth muscle), primary (smooth muscle, endothelial cells, fibroblasts), and stem-cell derived (cardiomyocytes, smooth muscle, endothelial cells) cell. Our tissue models also allow for bioinformatics analysis (RNAseq, proteomics, secretome) to be done on them, which makes them well-positioned for development of tunable bioprinted organ models. All biomaterial formulations that we offer can be used in bioprinting and have been validated to generate cell-supportive 3D scaffolds with high degree of reproducibility, high resolution, and up to anatomical scales.	We are looking for partners that can complement our expertise in bioprinting and biomaterials development with their know-how in efficient and reliable generation of target organ cell types from best cell sources, such as patient-derived stem cells, or other appropriate cell populations. We would also want to team up with partners that can address the large-scale manufacturing of the derived target organ cell types.	Technical area 3: organ biofabrication and testing;
AcroCyte Therapeutics Inc	Ying Chih Chang	CEO@acrocyte.com	jaffer.yang@acrocyte.com	Taiwan, New Taipei City/US, CA	Our patented R3CE technique (Rapid, Reproducible, Rare Cell 3D Expansion Platform) has been clinically proven to transform small patient specimens into functional organoids. The proposed R3CE transplant scheme begins with minimally invasive kidney cell retrieval via biopsies, rapid organoid formation and expansion, functional evaluation, and ends with the reintroduction of expanded organoids into the patient’s body.	3D Bioprinting team members, clinicians	Technical area 1: generate organ cell types;Technical area 2: large scale manufacturing ;
Florida Tech	Kunal Mitra	kmitra@fit.edu		Melbourne, FL	3D Bioprinting, disease modeling and treatment using 3D bioprinted tissue models	- expertise to generate cell types from best cell sources - expertise with large scale manufacturing of organ cell types	Technical area 3: organ biofabrication and testing;Technical area 2: large scale manufacturing ;
Cedars-Sinai Medical Center	Dmitriy Sheyn	Dmitriy.Sheyn@csmc.edu		Los Angeles	Our lab has experience in iPSC differentiation into various MSK lineages and tissues: bone, tendon, intervertebral disc cells and macrophages. We have access to biomanufactoriing facility in house and several in vivo small and large animal models. We have internal and external collaborators experts in translational research, biobehavioral test and imaging modalities.	We are looking for biomaterials experts and bio printing expert to team up for this application. Would be mostly interested in complex bio printing of composite tissues and materials.	Technical area 1: generate organ cell types;Technical area 3: organ biofabrication and testing;
Triple Ring Technologies	H. Roger Tang, PhD	rtang@tripleringtech.com	shemami@tripleringtech.com	Newark, California	We strive to be the most trusted partner for developing science-driven products in medtech, life sciences, and sustainability. In this role, we choose fulfilling problems, take on significant challenges, pull together diverse teams, collaborate fearlessly, and have a positive impact on people and the planet. To accomplish this vision, Triple Ring Technologies has assembled an interdisciplinary team of scientists, engineers, developers, and designers (25% with PhDs) that specializes in accelerating technologies up the TRL scale. For our clients, we ensure that technology will perform as desired when it needs to, and that their projects will achieve key milestones (be it performance or funding). We serve as a contractor providing services, or as a commercialization partner for early-stage technology for which proof-of-concept has been achieved by an academic/research laboratory. Services include but are not limited to, basic technology development, robust implementation of proof-of-concept results, prototype design and build for clinical use, and design for manufacturing. We are fully ISO 13485 certified.	We stand side-by-side with innovators and entrepreneurs to solve hard problems, launch breakthrough products, and create new businesses. We can provide the concept realization and technology development for FDA submission, clinical testing, and/or commercialization. We can start with just a concept (e.g., background intellectual property, or even just an idea); at the other end of the TRL scale, we can design or redesign for manufacturing or for FDA submission. Teaming partners would bring medical expertise, clinical experience, other technologies required, and big ideas that are not constrained by what they think is limiting in today’s technology. Prior experience in creating novel technology is not required.	Technical area 2: large scale manufacturing ;Technical area 3: organ biofabrication and testing;
University of Illinois Chicago	Eben Alsberg	ealsberg@uic.edu		Chicago, IL	3D and 4D bioprinting; cell-only bioprinting technology; new biomaterials and bioinks; bioprinting slurry development; tissue engineering; vascularization and angiogenesis; controlled bioactive factor delivery; cell condensation-based regenerative medicine	We're looking to team with partners with complementary expertise for addressing the 3 technical areas of this ARPA-H PRINT RFA.	Technical area 1: generate organ cell types;Technical area 3: organ biofabrication and testing;
Frontier Bio Corporation	Eric Bennett	eric@frontierbio.com	sam@frontierbio.com	Hayward, California	Frontier Bio innovates in 3D bioprinting and tissue engineering, focusing on 3 tissue areas: brain, blood vessels, and lung. Our skillset includes: bioprinting, vascularization, self-assembly, custom media/bio-ink, and custom bioreactors. Our bioprinted vascularized lung microtissue (>1 cm in length) reproduces the functional units of the distal lung, including the alevolar air sacs and bronchioles. The tissue boasts 9 relevant cell types, contains beating cilia, and generates mucus and surfactant. We uniquely utilize bioprinting coupled with tissue self-assembly to enable the production of functional lung microtissue structures that could not be produced by traditional bioprinting techniques. Our neural microtissues mature much faster than traditional neural organoids and form vessel-like structures in their interior, preventing necrotic core formation. Their longevity enables longer term in vitro studies. Our tissue-engineered blood vessels have been used by Mayo Clinic as a testing tool to examine the biological responses to an endovascular medical device. We design and print bioreactors for cell-seeding and maturation of our blood vessels. Our innovations and track record of completing contract tissue engineering projects has resulted in $4.7M in sales and $3.3M in funding (including an NSF SBIR grant). We work with great partners like Mayo Clinic and Intuitive Surgical.	We seek partners for technical area 1 and 2 (for generating and scaling cells for bioprinting)	Technical area 3: organ biofabrication and testing;
Sapphiros AiBio	Robin Y Smith	rsmith@sapphiros.ai	fpinto@sapphiros.ai	Boston, MA	Sapphiros AiBio has a fully consented biobank of over 85,000 cell lines. We have been able to generate multiple tissue types from PBMC reprogramming including cardiac, liver, neuro, dermal and other cell types. We have extensive experience in automated reprogramming and differentiation of diverse cell lines. Our biobank has also been HLA typed and we have allogeneic matches for >90% of the USA population.	We are looking to partner with firms that focus on TA3 (3d printing) technology. We have a GMP manufacturing partner that has our protocols for scale up of various cell types. We can also be of service to any organizations that need to leverage cell reprogramming and tissue generation. We can also screen cells and organs here in our Boston facility however we are seeking a biofabrication partner.	Technical area 1: generate organ cell types;Technical area 3: organ biofabrication and testing;Technical area 2: large scale manufacturing ;
North Carolina A&T State University	Jeffrey R. Alston	jralston1@ncat.edu	jraslto2@uncg.edu	Greensboro, NC	Our team excels in the field of biopolymer engineering, focusing on the innovative control of biopolymer properties during 3D printing. We have developed a patent-pending method that allows for precise customization of biopolymer hierarchical composition, porosity, and stiffness to create graded materials. These capabilities enable us to produce biopolymers that can potentially function as synthetic extracellular matrices, influencing cell proliferation and vascularization. Our approach is typically application-agnostic, but we are exploring the significant implications our biopolymers could have in various biomedical contexts. Our platform capabilities enable us to produce biopolymer prints that can potentially function as synthetic extracellular matrices, influencing cell proliferation and vascularization.	We seek collaboration with experts in tissue engineering and regenerative medicine who are enthusiastic about exploring the possibilities of using purely natural biopolymer "structural" inks. Our ideal partners will have the expertise to innovate with our biocompatible materials, applying them in ways that capitalize on their unique properties for advanced medical applications. Additionally, we are interested in partnering with a group that is actively developing 3D printing software capable of integrating detailed material property information into voxel-like print instructions. This collaboration will aim to enhance the precision and functionality of bioprinted constructs, optimizing them for specific clinical applications. Partners should be open to pioneering new treatment modalities that leverage our biopolymers as fundamental building blocks for tissue regeneration and repair.	Technical area 3: organ biofabrication and testing;
Ginkgo Bioworks	Jesse Dill	jdill@ginkgobioworks.com	kkiaee@ginkgobioworks.com	Boston, MA	Cell line phenotyping and engineering; iPSC characterization, selection, cultivation, and differentiation; immunogenicity assays.	We are looking for teaming partners with expertise in TAs 2 and 3; especially in scaled cultivation, GLP/GMP manufacturing, in vivo testing, bioreactor design and biofabrication, bioprinting and organ modeling, and perfusion of organs before transplantation.	Technical area 1: generate organ cell types;
3D BioLabs, LLC	Tyler Lieberthal	tlieberthal@3dbiolabs.com	jlachance@3dbiolabs.com	Watertown Massachusetts	The company’s focus has been to combine sophisticated 3D printers with elegant designs using computational fluid dynamics to produce scaffolding containing channels that mimic the natural blood vessels of organs and tissues. We combine sophisticated 3D printing technology, computational fluid dynamics, external in vitro bioreactor and in vivo surgical systems to create functioning man-made organs. Our approach harnesses the tools of tissue engineering and developmental biology to create large complex tissues and organs which can be matured in vitro in custom bioreactor systems and implanted with immediate blood flow. We have successfully used these components in many rat and pig based surgical procedures, including the insertion of cells. Our first product is a liver device which may serve as a lifesaving bridge to transplantation and ultimately, as destination therapy. Our platform technology can then be utilized to develop other organs and complex tissue replacement. 3D BioLabs was formed in December 2015 to build upon the success of Joseph Vacanti’s groundbreaking research while taking advantage of the rapid development of three-dimensional printing technology. 3D BioLabs core technology, virtually all of which resulted from Dr. Vacanti’s work at Harvard Medical School, was licensed from The General Hospital Corporation d/b/a Massachusetts General Hospital.	We are looking for partners with expertise in Technical Areas 1 and 2 to assist with cell source selection, validation, and scaling. We can then assemble cells with 3D printed scaffolds using our proprietary computational fluid dynamics-driver millifluidic designs and apply them to in vitro bioreactors and small animal models using our microvascular surgical techniques that we developed in >300 surgical experiments. With our academic partners, we can then implant large scaled scaffolds in a large animal model equipped with non-invasive Doppler monitoring of 3D printed scaffolds.	Technical area 3: organ biofabrication and testing;
University of Illinois Chicago	Debjit Pal	dpal2@uic.edu	ealsberg@uic.edu	Chicago Illinois	The current research focus is two-pronged. In one focus area, a group of faculty members is developing new bio-printing materials and new 3D bio-printing techniques for tissue engineering targeting various rheological properties, biocompatibility, size distribution of microgels, and stability, among others. However, such development is primarily based on the design of experiments (DoE). In another area, a group of faculty members is developing deep learning-based techniques to aid in constructing materials to complement DoE.	We are looking for potential teaming partners with access to a considerable amount of measurement data for different types of tissues targeting various applications. This data would be invaluable for building machine learning models.	Technical area 1: generate organ cell types;Technical area 3: organ biofabrication and testing;
Center for Regenerative Biotherapeutics, Mayo Clinic	William Faubion, MD	faubion.william@mayo.edu	allickson.julie@mayo.edu	Rochester, MN; Jacksonville, FL; Phoenix/Scottsdale, AZ	The Center for Regenerative Biotherapeutics (CRB) at Mayo Clinic collaborates with investigators focused on developing innovative therapies to regenerate and build damaged tissues and organs. Mayo Clinic’s biomanufacturing strategy within CRB is prioritizing Cell, Gene, and Viral Therapies, Bioprinting and Tissue Engineering. CRB incorporates a service model and partnering with Mayo Clinic Ventures, Business Development, Office of Regulatory Affairs and Clinical Trials department to effectively translate the technology to clinic. The process begins with identification of the most promising technologies in mid-to-late discovery phases, developing these technologies into early-phase clinical trials and setting up the technology for success and eventual licensing and partnership strategies. Mayo Clinic’s investment in biotherapeutics and manufacturing infrastructure will bring unique value to the biomanufacturing space. Mayo Clinic distinguishes itself from other healthcare organizations where we can partner with other academic institutions and industry for acceleration of products to patients. Mayo Clinic is the largest solid-organ transplant program in the country, we offer state-of-the-art clinical care models, access to transplant patient data, and blood/tissue samples. Our three Mayo sites are recognized for innovation and excellence in transplant care covering large areas of the country as well as biomanufacturing for biotherapeutics.	Create collaborative partnerships to enhance and drive innovative solutions for our patients while leveraging our unique capabilities in biomanufacturing and technology platforms. Access to patient cohorts (cell and tissues with normal physiology and pathophysiology, expertise in cell isolation, proliferation, and storage, aspects of manufacturing of both immune and nonimmune cells. Extensive experience in Clinical Trial and pathophysiology of organ disease, large scale manufacturing and ventures.	Technical area 1: generate organ cell types;Technical area 2: large scale manufacturing ;Technical area 3: organ biofabrication and testing;
Regemat 3D SL	Max Davantes	bd0@regemat3d.com	lab1@regemat3d.com	Granada, Spain	We develop human-scale bioreactors capable of mimicking various parts of human anatomy and physiology for the stimulation of patient-personalized 3D printed tissue substitutes, using our 3D Bioprinter and various associated extrusion tools.	We are looking for a US based tissue specialist interested in applying our technologies in the creation of new tissue patches or other applications in the liver, kidney, or heart tissues.	Technical area 3: organ biofabrication and testing;
Southwest Research Institute	Jian Ling, Ph.D.	jling@swri.org		San Antonio, Texas	SwRI has been developing a novel bioreactor technology that facilitate an automated, scalable, and closed manufacturing different types of mammalian adherent cells. This bioreactor technology is believed to address the TA 2 of the PRINT program.	We are looking for partners who have the expertise to address TA1 and TA2 of the PRINT program.	Technical area 2: large scale manufacturing ;
Syntax Bio	Brad Merrill	brad@cellgorithm.com	ryan@cellgorithm.com	Chicago, IL	Syntax Bio is a pre-clinical stage cell therapy company that uses delivery of genetic instruction sets to stem cells to program their differentiation. The company’s proprietary CRISPR-based synthetic biology system enables the epigenetic activation of endogenous genes in a sequentially delimited manner. We have used to generate several mesoderm and endoderm lineage cells from iPSC precursors.Our team also has unique expertise and leadership in conquering the large-scale manufacturing needed for clinical applications of iPSC-derived products.	Syntax Bio adds expertise in developing de novo iPSC differentiation procedures customized to the cellular identities and synthetic cellular properties necessary for constructing functional 3D printed organs. Timelines for our cellular programming technology (~4 weeks for project set up and ~2 weeks iteration cycle per differentiation experiment) enable rapid co-development with the other engineering parameters. We are looking for partners who can combine these assets with the 3D printing and manufacturing components of PRINT.	Technical area 1: generate organ cell types;Technical area 2: large scale manufacturing ;
State University of New York (SUNY) at Buffalo	Ruogang Zhao	rgzhao@buffalo.edu	rgzhao@buffalo.edu	Buffalo, NY	The application of 3D bioprinting in fabricating large-sized, solid hydrogel models that mimic human organs is challenged by slow printing speeds and low spatial resolution, which can affect part quality and the biological activity of the encapsulated cells. We have developed a rapid hydrogel stereolithography printing technology (FLOAT) that allows for the creation of centimeter-sized, cell-laden, and perfusable hydrogel models within minutes instead of hours. It is expected that combining this technology with appropriate cell types at physiologically-relevant densities will lead to the production of personalized, on-demand organs.	We look forward to collaborating with teams that have expertise in areas 1 and 2, i.e., generating organ-relevant cell types in large quantities.	Technical area 3: organ biofabrication and testing;
Trailhead Biosystems Inc.	Caroline Lawrence	clawrence@trailbio.com	dtrivedi@trailbio.com	Cleveland, OH	Trailhead creates optimized, wholly novel protocols for iPSC differentiation, yielding safer materials for cell therapy and better predictive models for research. Armed with our computerized experimental platform, we generate iPSC-derived cells of high clinical relevance. Our platform has already enabled us to create protocols for cells that no other company has cracked, such as somatostatinergic interneurons and vascular leptomeningeal cells (a vital element of the blood-brain barrier which themselves were only discovered in 2019). Moreover, we produce these cells by the billions in bioreactors, enabling standardization of cell therapy research inconceivable up to this point. We own our own laboratory and manufacturing facilities in Cleveland, Ohio. We currently offer about twenty different iPSC-derived cell types.	Anyone who uses iPSCs, whether in pre-clinical research or cell therapy: therapy developers, those in assay development or drug discovery, virology researchers, or any other kinds of research. Note that we can offer our cells at cGMP and can produce them on any cell line.	Technical area 2: large scale manufacturing ;Technical area 1: generate organ cell types;Technical area 3: organ biofabrication and testing;
Brigham and Women's Hospital and Harvard Medical School	Shuichi Mizuno	smizuno@rics.bwh.harvard.edu		Boston, MA	1. Long-term history for cell-based therapy • Our successful technology has been used for manufacturing autologous chondrocyte construction (NeoCart) to repair articular cartilage defects. 2. Our physiologically relevant culture system mimics daily human spinal motion and joint loading. • We successfully demonstrated that normal bovine caudal and moderately degenerated human intervertebral disc cells are capable to produce their own extracellular matrices under physiologically relevant culture conditions (hydrostatic pressure at 0.2 - 0.7 MPa, 0.5 Hz for 2 days followed by constant 0.3 MPa for 1 day, repetitively). These culture conditions and algorithms were chosen to mimic human spinal loading (bipedal); it is impossible to recapitulate using a quadrupedal organism. 3. Contribution to investigators through MGB Gene and Cell Therapy Institute, Biomimetic Cell/Tissue/Organoid Cell Process Studio (core function) • We offer our cell culture system for developing novel gene or cell therapy and using in preclinical studies as well as drug metabolism and pharmacokinetics.	We offer our existing or modified cell culture technologies for PRINT program. Incubation in 3D format under physiologically relevant culture conditions: • any type of cells • any type of cell construct • any type of cell process format Highlighted physiologically relevant culture conditions: • Hydrostatic pressure programable: between 0 – 3.5 MPa (skeletal tissue); 0 – 200 mmHg (blood pressure, sinusoid pressure, cerebrospinal fluid pressure). Cycle or constant or alternatively cyclic and constant. • Strain 0 – 0.4% synchronized with hydrostatic pressure or independently. • O2 gas concentration, CO2 gas concentration. • Perfusion speed, a medium bag (replaceable without culture interruption). Highlighted cell carrier, scaffold, devices… • High throughput 3D multicellular models using capillary modules, hollow fiber pouch modules. Scale up cell numbers or a cell construct with medium perfusion at programmable speed with medium. • Scale up using automated cell culture system (billion cells of iPSC or others).	Technical area 2: large scale manufacturing ;Technical area 3: organ biofabrication and testing;
Portal Biotechnologies	Mathias Pawlak	mathias@portal.bio	elizabeth@portal.bio	Watertown, MA	Portal has developed a next generation intracellular delivery platform for highly efficient, cost-effective cell engineering for a broad range of cell types and cargos. Portal has demonstrated robust delivery of many cargos (mRNA, siRNA, CRISPR, proteins, peptides) into diverse cell types including stem cells and primary human immune cells (T, B, NK cells, HSCs and iPSCs) while maintaining normal cell function. We are in the process of developing unique solutions that will allow both the rapid engineering of billions of cells within minutes as well as the integration of our delivery technology into robotic dispense mechanisms that could allow precise spatio-temporal 3D printing. These strengths of our technology will prove highly useful for the printing of 3D organs with enhanced function. The multitude of cell types that Portal is capable of engineering play important roles in organ function, homeostasis and repair. We are in the process of implementing our engineering technology into existing clinical scale manufacturing equipment which we anticipate will highly facilitate the ability to generate the large quantities of cellular material that is required for printing entire organs.	Within the PRINT program, Portal is specifically looking to collaborate with partners from both academia and industry that envision a 3D printed organ in which the individual cells representing the building blocks are engineered to enhance function and persistence. Portal has particular experience in engineering immune cells and stem cells. Immune cells, on one hand, are known to show many tissue-specific functions and can contribute to organ homeostasis and repair. Stem cells on the other hand can be instructed to differentiate into the fundamental building blocks of organs. In the context of 3D printing organs, these cells, particularly their engineered versions, are of high value. Partners within PRINT that require engineered immune cells and stem cells to build their organs are of specific interest to us as we recognize the synergistic value of their and our technologies. In summary, organs are highly complex assemblies of a multitude of different cell types and our technology has been demonstrated to be amenable to many different kinds of cell types. Therefore, we anticipate that additional cell types that will be required for the printing of organs can be successfully engineered with our technology in the future.	Technical area 2: large scale manufacturing ;Technical area 1: generate organ cell types;
Evia Bio, Inc	Adam Joules	Adam.joules@eviabio.com	advitiya.mahajan@eviabio.com	Minneapolis, Minnesota	Evia Bio specializes in advancing cryopreservation solutions with a primary focus on translating research into solutions for preserving cells safely and effectively. By replacing toxic agents like DMSO with non-toxic, FDA-approved ingredients—such as naturally occurring sugars, sugar alcohols, and amino acids— we aim to enhance the safety, quality, and accessibility of cryopreserved cells. Our research and technology not only addresses issues of stability and viability but also streamlines manufacturing processes, reducing costs and complexities. Leveraging machine learning algorithms, Evia Bio optimizes cryopreservation solutions and protocols for various cell types and mixed cell populations, expanding the potential for off-the-shelf products in research and clinical settings. Our research has covered protocol development from cell harvest through thawed product infusion with a deep focus on optimizing controlled rate freezing protocols from small vials to hundreds of mL of cells in cryobags. Evia Bio’s first principles and optimization approach promises increased yield, improved cell quality, and broader patient access to cutting-edge therapies, marking a significant step forward in the field of regenerative medicine.	We are interested in teaming up with partners that need cryopreservation and storage (cold chain) experts to integrate in existing bioprinting and cell manufacturing platforms to enhancing the viability, functionality, and shelf life of bioprinted constructs and manufactured cells.	Technical area 1: generate organ cell types;
Vascugen	David Mann	dmann@vascugen.com	kadeyanju@vascugen.com	Madison, WI	Vascugen is focused on validation studies leveraging our bank of iPSC-derived vascular stem cells (VSC200) manufactured under cGMP to support IND enabling studies and clinical development. Current areas of investigation include critical limb ischemia (CLTI), pulmonary hypertension (PAH), ocular retinopathies, supporting islet transplantation, and neural ischemia (stroke) recovery.	Vascugen is looking to leverage our robust Quality driven manufacturing process and existing VSC200 vascular stem cell product inventory in partnership with tissue fabrication/scaffold and other key tissue cell providers (iPSC, cardiac, hepatic, renal) to generate vascular building blocks an enable solid organ manufacture.	Technical area 1: generate organ cell types;Technical area 2: large scale manufacturing ;
Dimension Inx	Cole Johnson	colejohnson@dimensioninx.com		Chicago, IL	Dimension Inx is a biomaterials platform company that designs, develops, and manufactures therapeutic products to restore tissue and organ function. We engineer tissue microenvironments with tailored structural-to-functional properties that enhance the performance of regenerative therapies. Our product pipeline uses advanced biomaterials to improve the localization and engraftment of regenerative therapies within the host, e.g., cell therapies for T1D and liver diseases. We have deep expertise in the design, manufacture, and commercialization of regenerative and 3D-printed biomaterials with a focus on extrusion-based additive manufacturing. With our proprietary platform, we can control both material microstructure and composition without compromising the ability to form complex structures that demonstrate excellent handling properties and mechanical integrity. Our process allows for rapid material design, integration of chemically and thermally sensitive components, and multi-material 3D printing, in a scalable, commercially relevant manner. These capabilities allow the creation of biomaterials characterized by rapid tissue integration and vascularization allowing incorporated cells to better develop into functional tissues. Our platform has been commercially de-risked through FDA clearance and clinical launch of our initial therapeutic product, CMFlex™ - the first 3D-printed regenerative bone product cleared by the FDA. Notably, we manufacture this product in-house at our FDA-registered facility.	We are looking for partners with expertise in TA 2 and elements of TA3, especially GLP/GMP scaled manufacturing, bioreactor design, organ modeling, and the perfusion of organs before transplantation.	Technical area 3: organ biofabrication and testing;
37degrees, Inc.	Tilak Jain	tilak.jain@37-degrees.com		Chicago, IL	At 37degrees, Inc., we develop portable platforms for cell culture incubation, imaging and manipulation. Our prototype units are aimed to allow for live mammalian cell culture transport in-vitro between patient sites, labs and collaborator cities, without disruption of the cellular and tissue organization. Our units are palm-top, fully battery operated, globally tracked and include a variety of features for perfusion, live culture imaging, electrical recording and environmental condition maintenance. Members of our team have deep experience with complex system integration of hardware, software, fluidics, piezo-dispensing and automation systems for molecular and cellular biology applications.	We are looking for the lead scientific partner to direct and satisfy the overall goals of the PRINT project. We view ourselves as a very strong engineering and automation sub-collaborator who can support all technical areas, via innovative system integrated architectures. Our existing prototype technology can further support the transport and imaging of cell cultures at all levels of the process.	Technical area 1: generate organ cell types;Technical area 2: large scale manufacturing ;Technical area 3: organ biofabrication and testing;
UCSD	Tatiana Kisseleva	kmekeel@health.ucsd.edu	tkisseleva@health.ucsd.edu	La Jolla, California	Liver disease, cirrhosis, regeneration and transplantation	Bioprinting of livers for the treatment of disease	Technical area 1: generate organ cell types;Technical area 3: organ biofabrication and testing;
HP Inc Life Science Solutions	Jeff Nielsen	jeff.nielsen@hp.com	paul.benning@hp.com	Corvallis, Oregon	Our business has a lineup of microfluidics-based life science products and workflow solutions in the market (dispensing instruments, microfluidic devices, and software). Our current research is focused on microfluidics-based solutions for single cell isolation, sorting, transfection, 3D-tissue fabrication (spheroids, organoids, and layered structures), and reagent dispensing. Our printed 3D-tissue research has focused on using our digital dispensing technology to create anisotropic tissues with multiple cell types at variable ratios and concentrations in 3D space as well as ECM and tissue support structures. Numerous university and industry collaborations over more than a decade have created a suite of capabilities focused on generating tissues for life science research that are especially relevant to TA3.	While HP has meaningful TA3 bio-fabrication capabilities, we need a partner that can drive the overall program, from cell generation, to scale up, to in vivo testing. We are looking for organizations that can complement our TA3 organ bio-fabrication capabilities with TA1 and TA2 capabilities. We have microfluidics technology that may be useful in TA1 (cell sorting, isolation), but we do not have access to cell sources (TA1) or scale-up manufacturing of cells (TA2) and we have neither the in vivo testing capabilities of fabricated organs nor the bio-ink/ECM development capabilities required for TA3. We also recognize that while we have a strong base in high-resolution bio-fabrication capabilities, the printing of implantable organs may require a hybrid solution of multiple dispensing technologies. We also recognize that while we have a robust multi-physics modeling capability within HP, our biological modeling capabilities are less developed.	Technical area 3: organ biofabrication and testing;
LighTopTech Corp.	Cristina Canavesi, PhD, MBA	cristina@lightoptech.com		West Henrietta, NY	LighTopTech builds innovative optical instruments to bring to market disruptive technologies for noninvasive imaging on multiple scales. Combining wide-field of view imaging and three-dimensional sub-cellular imaging with machine learning methods, we achieve rapid screening and unbiased, automated characterization of 3D tissue constructs.	We are interested in partnering with teams that are looking for noninvasive, wide-field (10 mm x 10 mm single shot) rapid screening and 3D imaging of tissue	Technical area 1: generate organ cell types;Technical area 2: large scale manufacturing ;Technical area 3: organ biofabrication and testing;
SRI international	Joerg Martini	joerg.martini@sri.com		Palo Alto, California	Our group originates from the Palo Alto Research Center (Xerox) and has decades of printing experience, including: mixed materials, metals, semiconductors, pharmaceuticals, and bio-materials. We can 3-d print on existing structures with various printing methods (extrusion, inkjet, etc.) and access to CGMP certified inkjet heads that could be sterilized.	We are looking for a team that can use our capabilities in a subcontractor role. We can bring industrial scale-up of printing processes, including bio-printing to the team. We are used to performing on government contracts and have a track record of commercializing technologies.	Technical area 2: large scale manufacturing ;
Syracuse University	Pranav Soman	psoman@syr.edu		Syracuse, NY	New bioprinter hardware, control software, and bioinks. Bioreactors for long-term culture and characterizations Developed multiscale physics tissue-scale in silico models (In collaboration) Surgical anastomosis (suturing) of bioprinted constructs to blood supply using rat model (In collaboration) Developed first glomeruli-bowmans capsule (Kidney) on chip models (in collaborations)	Whole organ scanning and high resolution reconstruction of a CAD (stl) file. Access to large number of tissue-specific cells or ECM	Technical area 3: organ biofabrication and testing;
University of Chicago	Narutoshi Hibino	nhibino@bsd.uchicago.edu	Kevin.Lewellyn@bsd.uchicago.edu	Chicago, IL	We focus on developing cardiac tissue using scaffold-free bioprinting methods. Particularly in thick tissue creation, we've implemented methods to enhance cell viability and vascularization within the 3D tissue for better functionality and long-term survival. We are also employing both small and large animal models to evaluate the efficacy of these newly developed materials.	We are looking for partners who has expertise in stem cell differentiation, large scale culture, tissue preservation and transportation	Technical area 3: organ biofabrication and testing;
University of California, Riverside (UCR)	Huinan Hannah Liu	huinan.liu@ucr.edu	prue.talbot@ucr.edu	Riverside, California	UC-Riverside (UCR): UCR is located in Inland South California with one of the most diverse student bodies at any Research 1 (R1) institution in the country. In 2008, UCR became the first UC campus to be recognized as a Hispanic-Serving Institution (HSI), and have since attained status as an Asian American and Native American Pacific Islander-Serving Institution (AANAPISI). UCR is a member of Association of American Universities (AAU). UCR’s School of Medicine strives to improve the health of medically underserved, culturally, and economically diverse communities in the Inland South California. In Technical Area 1: UC-Riverside (UCR) has the capacity to generate organ cell types that represent diverse populations. In Technical Area 2: UCR has a collaborative team with expertise in stem cells, organoids, biomaterials, bioreactors, autonomous manufacturing, artificial intelligence for stem cell biology and biomanufacturing. In Technical Area 3: UCR has a collaborative team with expertise in 3D/4D printing, precision bio-fabrication, biomaterial design, extracellular matrix, and cell stimulation with engineered devices. UCR has the infrastructure and expertise for 3D printing of diverse materials such as metals, ceramics, polymers, composites, cells, proteins, and other biological materials. UCR is in the process of establishing a new facility for 3D bio-fabrication of mini-organs.	UCR has expertise and infrastructure in stem cells, organoid, 3D/4D printing, autonomous manufacturing, automation, data science, bioinformatics, machine learning, computational biology, nano- and micro-scale characterization, health disparity research, in vitro models, and small animal models in vivo. UCR campus serves diverse population in Inland South California and beyond, including medically and socioeconomically underserved communities. We are looking for collaborations with teams with complementary expertise, such as large animal models, GMP facilities, and clinical trial experience for organ testing. We would like to serve as a partner for the leading team and contribute our unique strengths and expertise in certain specific aspects of all three technical areas as described above.	Technical area 1: generate organ cell types;Technical area 2: large scale manufacturing ;Technical area 3: organ biofabrication and testing;
EE Partners, LLC	Robert Balke	Bob@eepartners.us.com		Boston, MA	We are capable of handling the responsibilities and requirements for Technical Area 1 (TA1) and Technical Area 2 (TA2). Our expertise includes generating organ cell types from the best cell sources (TA1) and scaling up manufacturing of these organ-specific cell types for (TA2) goals. For (TA1), our team excels in identifying cost-effective, multipotent, and immunocompetent cell sources, along with developing robust protocols for cell differentiation and expansion. Our methods ensure high purity and viability of organ-specific cell types, verified through rigorous assays and FDA-compliant standards. We also have novel proprietary systems that promise to meet cost, efficiency, and viability targets for low-cost distributed desktop manufacturing. In (TA2), we specialize in scaling up cell manufacturing processes to Good Manufacturing Practice (GMP) standards, creating master cell biobanks, and maintaining high cell viability and functionality during storage and transport. Our Quality Assurance and Quality Control (QA/QC) protocols ensure the production of safe, effective, and immunocompetent cells for organ biofabrication.	We are seeking a partner experienced in Technical Area 3 (TA3). The ideal partner would bring expertise in advanced bioprinting techniques, bioink formulation, bioreactor systems (or leverage our cell manufacturing technologies, and the ability to demonstrate the functional integration of bioprinted organs in animal models.	Technical area 1: generate organ cell types;Technical area 2: large scale manufacturing ;